Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients.
Candida
antimicrobial stewardship
bloodstream infections
candidemia
diagnostic biomarkers
β-glucan
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
28
12
2018
Statut:
epublish
Résumé
To assess the performance of the (1,3)-β-D-glucan (BDG) detection assay in a large cohort of patients with suspected candidemia who were admitted to non-intensive care unit hospital wards. This observational, retrospective cohort study was conducted in a 1,100-bed university hospital in Rome, where an infectious disease consultation team has been operational. Two groups of patients were included in the analysis: Group 1, patients with A total of 1,296 patients were studied. Of them, 100 patients (candidemic) were in Group 1 and the remaining 1,196 patients (controls) were in Group 2. There were no differences in demographic characteristics between patients of the two groups. According to the above cutoff values, sensitivity (%) and specificity (%) of the BDG assay ranged from 91 to 60.7 and 87.7 to 97.8, respectively, whereas the PPV (%) and NPV (%) ranged from 38.2 to 68.3 and 99.1 to 97.0, respectively. Serum BDG has a very high NPV in a population witĥ10% prevalence of candidemia. This NPV may support decisions to discontinue antifungal therapy in those patients who were empirically treated because of the suspect of candidemia.
Identifiants
pubmed: 30588044
doi: 10.2147/IDR.S181489
pii: idr-12-019
pmc: PMC6304239
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19-24Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Clin Infect Dis. 2004 Aug 1;39(3):309-17
pubmed: 15306996
Clin Infect Dis. 2005 Sep 1;41(5):654-9
pubmed: 16080087
Crit Care Med. 2006 Mar;34(3):730-7
pubmed: 16505659
Eur J Clin Microbiol Infect Dis. 2006 Jul;25(7):419-25
pubmed: 16773391
J Clin Microbiol. 2008 Mar;46(3):1009-13
pubmed: 18160456
Med Mycol. 2009;47 Suppl 1:S233-40
pubmed: 18720216
J Clin Microbiol. 2011 Feb;49(2):665-70
pubmed: 21106797
Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1453-60
pubmed: 21479838
Crit Care. 2011;15(5):R249
pubmed: 22018278
Clin Infect Dis. 2012 Mar 1;54(5):633-43
pubmed: 22198786
Clin Infect Dis. 2012 Jun;54(12):1739-46
pubmed: 22423135
PLoS One. 2012;7(3):e33705
pubmed: 22479431
Clin Infect Dis. 2013 May;56(9):1284-92
pubmed: 23315320
Am J Respir Crit Care Med. 2013 Nov 1;188(9):1100-9
pubmed: 23782027
J Clin Microbiol. 2013 Dec;51(12):4167-72
pubmed: 24108614
Infection. 2014 Apr;42(2):263-79
pubmed: 24272916
J Clin Microbiol. 2014 May;52(5):1453-8
pubmed: 24554755
J Antimicrob Chemother. 2014 Jul;69(7):1993-9
pubmed: 24659750
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:11-8
pubmed: 24661820
Intensive Care Med. 2014 Jun;40(6):808-19
pubmed: 24718642
J Clin Microbiol. 2014 Jul;52(7):2566-72
pubmed: 24829236
Clin Microbiol Rev. 2014 Jul;27(3):490-526
pubmed: 24982319
PLoS One. 2015 May 26;10(5):e0127534
pubmed: 26010361
PLoS One. 2015 Jul 06;10(7):e0131602
pubmed: 26146829
J Antimicrob Chemother. 2015 Nov;70(11):3107-15
pubmed: 26311840
J Antimicrob Chemother. 2016 Aug;71(8):2262-9
pubmed: 27125554
Clin Microbiol Infect. 2016 Jul;22(7):646.e5-8
pubmed: 27256062
J Clin Microbiol. 2016 Nov;54(11):2786-2797
pubmed: 27605710
Crit Care. 2017 Jul 10;21(1):176
pubmed: 28693606
Intern Emerg Med. 2018 Mar;13(2):199-204
pubmed: 29322386
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29444828
J Fungi (Basel). 2018 Feb 19;4(1):null
pubmed: 29463043
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29899003
Ann Surg. 1994 Dec;220(6):751-8
pubmed: 7986142
Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):103-9
pubmed: 8243032
J Infect. 1996 Jul;33(1):23-32
pubmed: 8842991